Zenas BioPharma, Inc. (ZBIO) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$31.76

From 52W high−27.03%

Volume2.49M

Market cap$2.05B

P/E (TTM)—

P/S (TTM)2053.1x

Div yield—

Key dataSep 18, 2026

Open

$31.76

From 52W high

−27.03%

Volume

2.49M

Market cap

$2.05B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−3.9x

P/E (TTM)

—

RSI (14)

48.2

MomentumView details →

1D Return

−1.47%

YTD Return

−13.47%

SummaryUpdated Jun 1, 2026

Zenas BioPharma, Inc. (NASDAQ:ZBIO) is a clinical-stage biopharmaceutical company founded in 2019 and headquartered in Waltham, Massachusetts. The company went public in September 2024 through an initial public offering. Zenas focuses on developing transformative immunology-based therapies for autoimmune and inflammatory diseases, with its lead product candidate obexelimab currently in clinical trials for multiple indications including rare autoimmune conditions and multiple sclerosis.

Ask drillr about Zenas BioPharma, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−3.9x

EV/Sales

1799.5x

P/S (TTM)

2053.1x

P/B (TTM)

8.3x

ProfitabilityView details →

Gross Margin

−5972.60%

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−196.03%

ROA (TTM)

−69.03%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

−93.33%

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

−55.28%

EPS CAGR 3Y

—

EBITDA YoY

—

MomentumView details →

1D Return

−1.47%

YTD Return

−13.47%

1Y Return

+65.89%

RSI (14)

48.2

vs 50D SMA

−0.07%

vs 200D SMA

+22.10%

Capital & dividendView details →

Debt/Equity

1.58x

Current Ratio

9.93x

Quick Ratio

9.93x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$1.77

EPS Surprise

−58.04%

Beats (12Q)

1/12

Next Q EPS Est

−$1.22

Avg Surprise (4Q)

−114.55%

Rev Surprise

−93.33%

Financials snapshotView financials →

Revenue (TTM)

1.00M

Net Income (TTM)

−484.38M

Op. CF (TTM)

−225.97M

Next earningsNov 12, 2026 →

Latest newsMore news →

Zenas BioPharma's CFO will transition to Strategic Advisor to the Board Chair at the end of September.38d ago

Zenas BioPharma expanded its Board of Directors with the appointment of Christy Oliger, who brings more than 30 years of global biopharmaceutical commercial and operating experience.38d ago

Similar companies

Nuvation Bio Inc.NUVB Recursion Pharmaceuticals, Inc.RXRX Kodiak Sciences Inc.KOD Vericel CorporationVCEL Biohaven Ltd.BHVN ADMA Biologics, Inc.ADMA Find similar companies →

Latest newsMore news →

Zenas BioPharma's CFO will transition to Strategic Advisor to the Board Chair at the end of September.38d ago Zenas BioPharma expanded its Board of Directors with the appointment of Christy Oliger, who brings more than 30 years of global biopharmaceutical commercial and operating experience.38d ago